A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

BACKGROUND: The epidermal growth factor receptor (EGFR) monoclonal IgG(1) antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high response a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomark Res
Hlavní autoři: Espinosa-Cotton, Madelyn, Fertig, Elana J., Stabile, Laura P., Gaither-Davis, Autumn, Bauman, Julie E., Schmitz, Sandra, Gibson-Corley, Katherine N., Cheng, Yinwen, Jensen, Isaac J., Badovinac, Vladimir P., Laux, Douglas, Simons, Andrean L.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6636109/
https://ncbi.nlm.nih.gov/pubmed/31346466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-019-0164-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky